Johnson & Johnson (NYSE:JNJ) today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and ...

Hello. This is the PR Practice Academy.This is our free session where we read current events through the lens of public ...

Expert and company perspectives on the role of amivantamab in advancing first-line treatment “Patients with recurrent or metastatic head and neck cancer continue to face a poor prognosis, highlighting ...

IntroductionOn October 1, 2026 (Reiwa 8), the amended portions of the Equal Employment Opportunity Law (Act on Securing, Etc.

RTX Q3 2026 earnings call recap: raised sales, EPS and free cash flow outlook; record $340B backlog and missile awards.

Explore how essential oils may support microbiome balance across the gut, respiratory, and urinary systems through targeted ...

A new neuro-symbolic framework called SymbolFusion applies explicit literary relation constraints to graph learning, ...

NeOnc stands out in this group for the challenge it is confronting. Recurrent high-grade brain cancer remains an exceptionally difficult treatment setting. The National Cancer Institute notes that ...

Kim Dong-chul, CEO of Korea Electric Power Corporation (KEPCO), pushed back on October 12 during a National Assembly audit against claims ...

Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2 trial evaluating petosemtamab,an investigational ...

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of ...

Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...